AstraZeneca (AZN) Rating Reiterated by Citigroup
Citigroup reiterated their buy rating on shares of AstraZeneca (LON:AZN) in a research report sent to investors on Thursday morning. They currently have a GBX 6,200 ($85.66) price objective on the biopharmaceutical company’s stock.
Several other analysts also recently weighed in on AZN. Investec lifted their target price on shares of AstraZeneca from GBX 4,900 ($67.70) to GBX 5,500 ($75.99) and gave the company a buy rating in a report on Monday, November 6th. JPMorgan Chase & Co. reaffirmed a neutral rating on shares of AstraZeneca in a report on Wednesday, November 1st. Jefferies Group set a GBX 5,075 ($70.12) target price on shares of AstraZeneca and gave the company a neutral rating in a report on Monday, February 26th. UBS Group set a GBX 4,550 ($62.86) target price on shares of AstraZeneca and gave the company a neutral rating in a report on Tuesday, February 6th. Finally, Goldman Sachs Group set a GBX 3,800 ($52.50) target price on shares of AstraZeneca and gave the company a sell rating in a report on Monday, February 19th. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of Hold and an average price target of GBX 5,199.70 ($71.84).
Shares of AstraZeneca (AZN) opened at GBX 4,726 ($65.29) on Thursday. The firm has a market cap of $59,810.00 and a PE ratio of 2,747.67. AstraZeneca has a fifty-two week low of GBX 4,260 ($58.86) and a fifty-two week high of GBX 5,520 ($76.26).
In other AstraZeneca news, insider Philip A. J. Broadley purchased 415 shares of AstraZeneca stock in a transaction on Friday, February 2nd. The shares were bought at an average price of GBX 4,846 ($66.95) per share, with a total value of £20,110.90 ($27,785.16).
TRADEMARK VIOLATION WARNING: “AstraZeneca (AZN) Rating Reiterated by Citigroup” was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this report on another site, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this report can be viewed at https://www.dailypolitical.com/2018/03/05/astrazeneca-azn-rating-reiterated-by-citigroup.html.
AstraZeneca Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.